Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Altoona, Pennsylvania Clinical Trials

A listing of Altoona, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (22) clinical trials

NOVOCART 3D for Treatment of Articular Cartilage of the Knee

Subjects with articular knee defects will be randomized to receive either Microfracture or NOVOCART 3D. Subjects will be followed for five years in total and will be evaluated for safety and efficacy.

Phase

1.45 miles

Learn More »

Micronized dHACM Injectable for the Treatment of Achille Tendonitis

Approximately 158 subjects will be enrolled in this study. Each patient will receive 1 injection and be evaluated for efficacy and safety during a 12 month observation period. Randomization will be 1:1. The study is expected to be completed in 24 months, inclusive of enrollment and follow-up of all subjects.

Phase

1.45 miles

Learn More »

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

A randomized, multicenter, double-blind, placebo- controlled parallel-group study to determine the efficacy and safety of QAW039, compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult and adolescent ( 12 years) patients with uncontrolled asthma with respect to change from baseline in forced expiratory volume in 1 second ...

Phase

1.45 miles

Learn More »

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

This is an open-label, multicenter study designed to evaluate efficacy and safety of reducing daily oral corticosteroid (OCS) use after initiation of 30 mg dose of benralizumab administered subcutaneously (SC) in patients with severe eosinophilic asthma receiving high-dose inhaled corticosteroid (ICS)/long-acting 2 agonist (LABA) and OCS with or without additional ...

Phase

1.45 miles

Learn More »

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

This is an international, multicentre, parallel-group, event-driven, randomised, double-blind study in patients with HFpEF, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death and heart failure ...

Phase

1.45 miles

Learn More »

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

1.45 miles

Learn More »

Micronized dHACM Injectable for the Treatment of Plantar Fasciitis

Approximately 164 patients will be enrolled in this study. Each patient will receive 1 injection and be evaluated for efficacy and safety during a 6-month observation period. Randomization will be 1:1. The study is expected to be completed within 24 months, inclusive of enrollment and follow-up of all subjects.

Phase

1.61 miles

Learn More »

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

The purpose of this multi-center study in non-dialysis subjects with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.

Phase

6.72 miles

Learn More »

A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).

Phase

6.72 miles

Learn More »

A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in the patients with moderately to severely active psoriatic arthritis (PsA).

Phase

6.72 miles

Learn More »